**Author details**

Anuratha Sakthianandeswaren1,2, Polly Sabljak1 , Meg J. Elliott1 , Michelle Palmieri1,2 and Oliver M. Sieber1,2\*

1 Systems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

2 Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia

\*Address all correspondence to: sieber.o@wehi.edu.au

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**119**

*Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab…*

[9] Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, et al. Pharmacokinetic and pharmacodynamic

perspectives on the clinical drug development of panitumumab. Clinical Pharmacokinetics. 2010;**49**(11):729-740

[10] Inoue Y, Hazama S, Iwamoto S, Miyake Y, Matsuda C, Tsunedomi R, et al. FcgammaR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer. Molecular Diagnosis

& Therapy. 2014;**18**(5):541-548

[11] Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clinical Cancer Research. 2007;**13**(5):1552-1561

[12] Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology.

[13] Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, et al. All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treatment Reviews. 2011;**37**(3):221-233

[14] Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Acquired resistance to EGFR-targeted therapies in

2014;**8**(6):1084-1094

colorectal cancer. Molecular Oncology.

[15] Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nature Reviews. Cancer. 2003;**3**(6):459-465

2014;**15**(6):569-579

*DOI: http://dx.doi.org/10.5772/intechopen.80690*

[1] Surveillance, Epidemiology, and End Results Program SEER Facts and Figures. Colorectal Cancer. National Cancer Institute. 2018. [cited Jul 20, 2018]. Available from: https://seer. cancer.gov/statfacts/html/colorect.html

**References**

[2] Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 2016;**27**(8):1386-1422

[3] Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget.

[4] Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biology & Therapy.

[5] Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nature Reviews. Cancer. 2013;**13**(9):663-673

[6] Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Molecular Oncology.

[7] Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Annals of Oncology.

2017;**8**(3):3980-4000

2011;**11**(9):777-792

2018;**12**(1):3-20

2005;**16**(1):102-108

2001;**92**(5):1331-1346

[8] Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer. *Predictive Biomarkers for Monoclonal Antibody Therapies Targeting EGFR (Cetuximab… DOI: http://dx.doi.org/10.5772/intechopen.80690*
